07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Proteostasis Therapeutics Inc management update

Proteostasis Therapeutics Inc., Cambridge, Mass.   Business: Pulmonary, Endocrine/Metabolic, Neurology   Hired: Meenu Chhabra as president, CEO and a director, formerly president and CEO of Allozyne Inc.   ...
08:00 , Feb 3, 2014 |  BioCentury  |  Finance

Bicoastal incubation

Bicoastal incubation In parallel with raising a fourth fund, the new CEO of Accelerator Corp. plans to expand the bioincubator's presence beyond Seattle by setting up shop in New York, a region he believes offers a...
07:00 , Aug 19, 2013 |  BioCentury  |  Product Development

The next wave in ADCs

After about 25 years of development, antibody-drug conjugates have gained acceptance as a validated approach to the targeted killing of cells, with two drugs approved in the past two years. While Seattle Genetics Inc. and...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

Integrated Diagnostics management update

Integrated Diagnostics Inc., Seattle, Wash.   Business: Diagnostic   Hired: John Bencich as CFO, formerly CFO of Allozyne Inc.   ...
07:00 , Jul 9, 2012 |  BioCentury  |  Tools & Techniques

Taking ADCs beyond oncology

Merck & Co. Inc. partnered with Ambrx Inc. because the pharma hopes to build upon the biotech's near-decade of experience in site-specific peptide modification to move antibody-drug conjugates beyond oncology. Last month, Merck agreed to pay...
07:00 , May 28, 2012 |  BioCentury  |  Finance

Pressing the Accelerator

Pressing the Accelerator Venture-backed incubator Accelerator Corp. is raising a fourth fund that it expects to close by year end, Chairman and CEO Carl Weissman told BioCentury. Weissman, who also is a managing director at OVP Venture...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Company News

Poniard cancer news

Poniard announced Ronald Martell, who resigned as CEO, was appointed chairman. He replaces Jerry McMahon who is resigning along with directors E. Rolland Dickson, Gary Lyons and Nicholas Simon. Poniard said the CEO position will...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Allozyne, Poniard deal

The companies mutually terminated their reverse merger after determining the stock of the combined company would not qualify for listing on NASDAQ, a condition for the close of the deal. Poniard said its board is...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Clinical News

AZ01: Phase Ib data

A double-blind, placebo-controlled, multiple ascending-dose, European Phase Ib trial in 48 healthy volunteers showed that various doses of AZ01 given at 14- or 28-day intervals were well tolerated. Allozyne plans to start Phase III testing...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Financial News

Poniard financial update

Poniard Pharmaceuticals Inc. (NASDAQ:PARD), South San Francisco, Calif.   Business: Cancer   Date announced: 9/6/11   Poniard said NASDAQ granted the company's request to remain listed on the exchange subject to certain conditions, including: implementation of a reverse...